Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation

Rogoff, Edward E.; Hilaris, Basil S.; Huvos, Andrew G.

doi:10.1002/1097-0142(197309)32:3<656::aid-cncr2820320319>3.0.co;2-u

Cited by 59 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most of the patients, death eventually occurs as a result of local–regional progression within the abdominal cavity 5. In historical case‐series, treatment by palliative surgery, systemic/intra‐peritoneal chemotherapy, and abdominal irradiation was disappointing, with a median survival of about 12 months (Table I) 8–16.…”

Section: Introductionmentioning

confidence: 99%

Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research

Baratti¹,

Kusamura²,

Deraco³

2011

Journal of Surgical Oncology

View full text Add to dashboard Cite

Diffuse malignant peritoneal mesothelioma (DMPM) is an uncommon and locally aggressive tumor with poor prognosis. Currently, no standard therapy is available. The biology of this disease is still poorly understood. We performed a systematic search of relevant studies on clinical management and biological research of DMPM. Trials were selected using a predetermined protocol. The current evidence suggests that cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) results in improved survival. Biological understanding of DMPM is currently evolving.

show abstract

Section: Introductionmentioning

confidence: 99%

Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research

Baratti¹,

Kusamura²,

Deraco³

2011

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Bei der Chemotherapie gibt es bislang keinen Standard. Kombinationen von Doxorubicin, Bleomycin, Cisplatin und Mitomycin oder Paclitaxel und Cisplatin errreichen mit 44 % bis 66 % jedoch bessere Ansprechraten als Monotherapien, deren Response nur bei 10±20 % liegt [8,10,14,17]. Die besten Ergebnisse erreicht zur Zeit ein Therapieregime des Washington Cancer Institute.…”

Section: Diskussionunclassified

Das maligne peritoneale Mesotheliom - eine seltene Differenzialdiagnose der Peritonealkarzinose

Hartmann¹,

Krones²,

Klinge³

et al. 2004

Viszeralchirurgie

View full text Add to dashboard Cite

EinleitungPeritoneale Mesotheliome sind im klinischen Alltag selten [15,19]. Nur 20±30 % aller Mesotheliom-Fälle gehen vom Peritoneum aus. Weitaus häufiger findet man die pleurale Lokalisation (viszerale und parietale Pleura), das Mesotheliom des Perikards ist eine Rarität [3, 7]. Aufgrund ihrer unspezifischen Symptome werden peritoneale Mesotheliome meist erst im fortgeschrittenen Stadium erkannt. Die operative Therapie beschränkt sich dann häufig auf die Wiederherstellung der Magen-Darm-Passage [15]. Die Standard-Diagnostik ergibt ohne immunhistochemische Zusatzuntersuchungen häufig die Fehldiagnose einer Peritonealkarzinose als Folge eines fortgeschrittenen gastrointestinalen Tumors. Die mittlere Überlebensrate liegt dann lediglich bei ca. 12 Monaten, lässt sich jedoch für das maligne peritoneale Mesotheliom mit dem richtigen multimodalen Therapiekonzept Zusammenfassung Das maligne peritoneale Mesotheliom ist ein seltener Tumor. Die Literatur bietet neben Einzelfallbeschreibungen nur kleine Fallzahlen. Der Tumor verursacht in der Regel lediglich uncharakteristische abdominelle Beschwerden, so dass die Erkrankung häu-fig erst im fortgeschrittenen Stadium erkannt wird. Differenzialdiagnostisch ist das maligne Mesotheliom trotz aller technischen Möglichkeiten nur erschwert von sekundären Peritonealkarzinosen abzugrenzen, die sichere Diagnose lässt sich nur immunhistochemisch stellen. Die Therapie muss multimodal angelegt werden. Im Gegensatz zu Peritonealkarzinosen anderer Genese und ähnlich zur Therapie von Ovarialkarzinomen sind Resektion oder Debulking und eine kombinierte Chemotherapie indiziert. Die sonst sehr eingeschränkte Lebenserwartung liegt dann zwischen 50±60 Monaten. Schlüsselwörter Malignes peritoneales Mesotheliom´Peritonealkarzinose´mul-timodale Therapie AbstractThe malignant peritoneal mesothelioma is a rare tumor. There exist only a few publications with mostly individual case reports. The tumor causes most of the time only abdominal discomfort. Thus, it is frequently diagnosed in a progressed stage and despite all technical possibilities it is hard to differentiate from secondary peritoneal carcinosis. The correct diagnosis can only be confirmed immunhistologically. A multimodal therapy must be performed. In contrast to peritoneal carcinosis of other genesis and similar to the treatment of carcinomas of the ovaries resection or debulking operation with a combined chemotherapy must be performed. Then, the usually limited life expectancy can be extended to 50 to 60 months. Kasuistik 313Heruntergeladen von: University of Pittsburgh. Urheberrechtlich geschützt.

show abstract

“…Patients have been given external whole abdominal radiation with and without intraperitoneal radioactive P32 [16] and with and without systemic chemotherapy [17,18] or cytoreductive surgery [19]. No patient was rendered disease-free, and long-term survival was rare.…”

Section: Treatmentmentioning

confidence: 99%

Peritoneal mesothelioma

Taub

Keohan

Chabot

et al. 2000

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Malignant peritoneal mesothelioma is an aggressive neoplasm that rapidly spreads within the confines of the abdominal cavity to involve most accessible peritoneal and omental surfaces. Current treatments are unsatisfactory, and new approaches are needed. We have noted prolonged survival in selected patients after intensive multimodality treatment. Our current experimental regimen includes initial laparotomy with omentectomy, resection of peritoneal implants, and placement of bilateral peritoneal Port-a-Caths (Sims Deltec, Inc., St. Paul, MN); repeated courses of intraperitoneal chemotherapy with doxorubicin, cisplatin, and interferon gamma; second-look laparotomy and intraoperative hyperthermic perfusion with mitomycin and cisplatin; and whole abdominal radiation. Patients with peritoneal mesothelioma who are not candidates for this approach can sometimes be palliated with systemic (intravenous) chemotherapy using doxorubicin or mitomycin, alone or in combination with cisplatin or carboplatin. Newer agents such as gemcitabine and multitargeted antifolate (pemetrexed disodium, LY231514) show promise of greater effectiveness.

show abstract

Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation

Cited by 59 publications

References 12 publications

Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research

Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research

Das maligne peritoneale Mesotheliom - eine seltene Differenzialdiagnose der Peritonealkarzinose

Peritoneal mesothelioma

Contact Info

Product

Resources

About